Common Contracts
3 similar Underwriting Agreement contracts by Checkpoint Therapeutics, Inc., Viking Therapeutics, Inc.
13,400,000 SHARES CHECKPOINT THERAPEUTICS, INC. COMMON STOCK UNDERWRITING AGREEMENTUnderwriting Agreement • November 20th, 2019 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
Checkpoint Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule V hereto (the “Underwriters”), for whom National Securities Corporation is acting as representative (the “Representative”), an aggregate of 13,400,000 authorized but unissued shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and, at the election of the Underwriters, upon the terms and conditions stated herein, up to 2,010,000 additional shares (the “Additional Shares”) of Common Stock solely to cover over-allotments, if any (the Firm Shares and the Additional Shares that the Underwriters elect to purchase pursuant to Section 3 hereof being collectively called the “Securities”).
4,600,000 SHARES CHECKPOINT THERAPEUTICS, INC. COMMON STOCK UNDERWRITING AGREEMENTUnderwriting Agreement • March 8th, 2018 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
Viking Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • April 1st, 2016 • Viking Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Viking Therapeutics, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of shares (the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share ( “Common Stock”) and warrants to purchase an aggregate of shares of Common Stock (the “Warrants,” and collectively with the Firm Shares, the “Firm Securities”). In addition, the Company proposes to grant to the Underwriters an option to purchase from the Company up to an additional shares of Common Stock (the “Option Shares”) and/or Warrants to purchase up to an additional shares of Common Stock (the “Option Warrants”) for the purpose of covering over-allotments in connection with the sale of the F
